Why the study?
COVID-19 triggers inflammation increasing thrombosis and multi-system organ dysfunction, but the optimal prophylactic and therapeutic regimens remain unclear.
Key points are not available for this paper at this time.
Design
Review
Thromboprophylaxis in COVID-19 remains uncertain; leaves open optimal regimens to prevent microvascular thrombosis and organ dysfunction.
COVID-19 infection triggers a heightened inflammatory response which in turn, increases thrombosis and thromboembolism. Microvascular thrombosis has been detected in various tissue beds which may account for some of the multi-system organ dysfunction associated with COVID-19. Additional research is needed to understand which prophylactic and therapeutic drug regimens are best for the prevention and treatment of thrombotic complications of COVID-19.
No takes yet. Share an insight, caveat, or question.
Kankaria et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: